National Institutes of Health

Enclosed is the fourth edition of a book that is dedicated to the medical and social issues of individuals with sickle cell disease. This publication, which was developed by physicians, nurses, psychologists, and social workers who specialize in the care of children and adults with sickle cell disease, describes the current approach to counseling and also to management of many of the medical complications of sickle cell disease. Each chapter was prepared by one or more experts and then reviewed by several others in the field. Additional experts reviewed the entire volume. This book is not the result of a formalized consensus process but rather represents the efforts of those who have dedicated their professional careers to the care of individuals with sickle cell disease. The names of the authors, their affiliations, and their e-mail addresses are listed in the front of the book.

Cells and DNA - Cells, genes, and chromosomesMutations and Health - Gene mutations, chromosomal changes, and conditions that run in familiesHow Genes Work - Proteins, cell growth, and cell divisionGene Families - Groups of genes that share important characteristicsInheriting Genetic Conditions - Inheritance patterns and understanding riskGenetics and Human Traits - How genes influence various human characteristicsGenetic Consultation - Finding and visiting a genetic counselor or other genetics professionalGenetic Testing - Benefits, costs, risks, and limitations of genetic testingNewborn Screening - Testing all babies in their first days of life for certain disorders and conditionsGene Therapy - Experimental techniques, safety, ethics, and availabilityThe Human Genome Project - Sequencing and understanding the human genomeGenomic Research - Next steps in studying the human genomePrecision Medicine - Disease treatment and prevention strategies tailored to variability in genes, environment, and lifestyle

A gene mutation is a permanent alteration in the DNA sequence that makes up a gene, such that the sequence differs from what is found in most people. Mutations range in size; they can affect anywhere from a single DNA building block (base pair) to a large segment of a chromosome that includes multiple genes. Gene mutations can be classified in two major ways: - Hereditary mutations are inherited from a parent and are present throughout a person's life in virtually every cell in the body. These mutations are also called germline mutations because they are present in the parent's egg or sperm cells, which are also called germ cells. When an egg and a sperm cell unite, the resulting fertilized egg cell receives DNA from both parents. If this DNA has a mutation, the child that grows from the fertilized egg will have the mutation in each of his or her cells.- Acquired (or somatic) mutations occur at some time during a person's life and are present only in certain cells, not in every cell in the body. These changes can be caused by environmental factors such as ultraviolet radiation from the sun, or can occur if a mistake is made as DNA copies itself during cell division. Acquired mutations in somatic cells (cells other than sperm and egg cells) cannot be passed on to the next generation.

A particular disorder might be described as "running in a family" if more than one person in the family has the condition. Some disorders that affect multiple family members are caused by gene mutations, which can be inherited (passed down from parent to child). Other conditions that appear to run in families are not caused by mutations in single genes. Instead, environmental factors such as dietary habits or a combination of genetic and environmental factors are responsible for these disorders. It is not always easy to determine whether a condition in a family is inherited. A genetics professional can use a person's family history (a record of health information about a person's immediate and extended family) to help determine whether a disorder has a genetic component. He or she will ask about the health of people from several generations of the family, usually first-, second-, and third degree relatives.

This book will cover the following questions: What are proteins and what do they do? How do genes direct the production of proteins? Can genes be turned on and off in cells? What is the epigenome? How do cells divide? How do genes control the growth and division of cells? How do geneticists indicate the location of a gene?

This book will answer these Questions: Are fingerprints determined by genetics? Is eye color determined by genetics? Is intelligence determined by genetics? Is handedness determined by genetics? Is the probability of having twins determined by genetics? Is hair texture determined by genetics

Choosing to take part in clinical research is an important personal decision Your decision to participate will depend on your interests, needs, and expectations about research. This brochure, prepared by the National Institute of Mental Health (NIMH), provides answers to common questions about volunteering for mental health clinical research NIMH is part of the National Institutes of Health (NIH), the primary Federal agency for conducting and supporting medical research. Our goal is to give you basic information about clinical research and help you make a decision about whether to participate Please review this information and discuss it with those close to you As you read, write down questions you may want to ask

On April 2, 2013, President Obama launched the BRAIN Initiative to "accelerate the development and application of new technologies that will enable researchers to produce dynamic pictures of the brain that show how individual brain cells and complex neural circuits interact at the speed of thought." In response to this Grand Challenge, NIH convened a working group of the Advisory Committee to the Director, NIH, to develop a rigorous plan for achieving this scientific vision. To ensure a swift start, the NIH Director asked the group to deliver an interim report identifying high priority research areas that should be considered for the BRAIN Initiative NIH funding in Fiscal Year 2014. These areas of priority are reflected in this report and, ultimately, will be incorporated into the working group's broader scientific plan detailing a larger vision, timelines and milestones. The goals voiced in the charge from the President and from the NIH Director are bold and ambitious. The working group agreed that in its initial stages, the best way to enable these goals is to accelerate technology development, as reflected in the name of the BRAIN Initiative: "Brain Research through Advancing Innovative Neurotechnologies." The focus is not on technology per se, but on the development and use of tools for acquiring fundamental insight about how the nervous system functions in health and disease. In addition, since this initiative is only one part of the NIH's substantial investment in basic and translational neuroscience, these technologies were evaluated for their potential to accelerate and advance other areas of neuroscience as well. In analyzing these goals and the current state of neuroscience, the working group identified the analysis of circuits of interacting neurons as being particularly rich in opportunity, with potential for revolutionary advances. Truly understanding a circuit requires identifying and characterizing the component cells, defining their synaptic connections with one another, observing their dynamic patterns of activity in vivo during behavior, and perturbing these patterns to test their significance. It also requires an understanding of the algorithms that govern information processing within a circuit, and between interacting circuits in the brain as a whole. With these considerations in mind, the working group consulted extensively with the scientific community to evaluate challenges and opportunities in the field. Over the past four months, the working group met seven times and held workshops with invited experts to discuss technologies in chemistry and molecular biology; electrophysiology and optics; structural neurobiology; computation, theory, and data analysis; and human neuroscience (a full list of speakers and topics can be found in Appendix A). Workshop discussions addressed the value of appropriate experimental systems, animal and human models, and behavioral analysis. Each workshop included opportunity for public comments, which were valuable for considering the perspectives of patient advocacy groups, physicians, and members of the lay public. Although we emphasize that this is an interim report, which will develop with much additional advice before June 2014, certain themes have already emerged that should become core principles for the NIH BRAIN Initiative.

The decline in U. S. smoking prevalence since the publication of the first Surgeon General's Report in 1964 has been hailed as one of the greatest public health accomplishments of the past century. Forty four million Americans-almost half of those who ever smoked-have quit, and lung cancer death rates have decreased greatly as a result. As a nation, we've launched wide-reaching tobacco control programs in worksites, schools, communities, and all 50 states, and we've witnessed enormous shifts in social norms, policies, and public attitudes. Growth in clean indoor-air laws and smoking restrictions have made quit-smoking cues "persistent and inescapable", and new data shows that tobacco price increases and mass media cessation campaigns can significantly increase population quit rates. Over the last three decades, we have developed effective clinical treatments-psychosocial and pharmacological-and seen the publication and update of authoritative practice guidelines recommending evidence based treatments that, if universally applied, could double our national annual quit rate in a highly cost-effective way. Prospects for preventing and treating tobacco use and addiction have never been better. Yet the papers in this monograph, Those Who Continue to Smoke: Is Achieving Abstinence Harder and Do We Need to Change Our Interventions?, raise important questions about what it will take to build on the successes of the last century and, in particular, on the last few decades of research and practice. While efforts to promote tobacco cessation need to be part of a much broader national tobacco control strategy that emphasizes prevention, it is clear that the greatest gains in reducing tobacco-caused morbidity, mortality, and health care costs in the next 30 to 40 years will come from helping addicted smokers quit. Further declines in adult smoking are likely to strengthen prevention efforts as well, since adult smoking is a critical determinant of social norms and a vector for youth initiation. In this context, the findings presented in this monograph have important implications for the next generation of research and practice to help addicted smokers quit. Specifically, these papers and the findings they present indicate that helping more smokers quit will require: (1) developing more powerful treatments that can break through the 25% to 30% quit-rate ceiling achieved with our best existing treatments; (2) refining, targeting and tailoring treatments for high-risk populations; (3) greatly improving surveillance of quitting patterns and determinants; (4) developing combined clinical-public health approaches that harness synergies between evidence based clinical treatments, and macro-level policy and environmental cessation strategies; and (5) improving the use of and demand for treatments that work.